Review





Similar Products

94
fluidigm 3168012a
3168012a, supplied by fluidigm, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc12645211-67-9-6?v=fluidigm
Average 94 stars, based on 1 article reviews
3168012a - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc phospho stat6 y641
Phospho Stat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pm41203944-56-10-12?v=Cell+Signaling+Technology+Inc
Average 86 stars, based on 1 article reviews
phospho stat6 y641 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

86
Cell Signaling Technology Inc pstat6 y641
Pstat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc12549784-406-36-8?v=Cell+Signaling+Technology+Inc
Average 86 stars, based on 1 article reviews
pstat6 y641 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc anti pstat6 y641
Anti Pstat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc12549784-31-0-3?v=Cell+Signaling+Technology+Inc
Average 95 stars, based on 1 article reviews
anti pstat6 y641 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

86
Huabio Inc p y641 stat6
P Y641 Stat6, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pm40897694-73-24-49?v=Huabio+Inc
Average 86 stars, based on 1 article reviews
p y641 stat6 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
ABclonal Biotechnology p-stat6 (y641) ap1390 antibody
P Stat6 (Y641) Ap1390 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc12269164-83-74-75?v=ABclonal+Biotechnology
Average 90 stars, based on 1 article reviews
p-stat6 (y641) ap1390 antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc phospho-stat6 (y641) antibody
Effects of ESB on STAT3 phosphorylation in RAW 264.7 cells. RAW 264.7 mouse macrophages were stimulated with IL-6 (100 ng/mL, A, B) or IL-4 (100 ng/mL, C, D) in the presence or absence of ESB (50 and 100 μg/mL). After 24 h, the levels of phosphorylated and total STAT3 and <t>STAT6</t> were analyzed using Western blot analysis. Actin served as a loading control. Representative blot images from three independent experiments are shown (A, C). The ratio of phosphorylated to total protein was quantified by measuring band intensity (B, D). Data are presented as the mean ± SD of three independent experiments. Statistical significance was evaluated using one-way ANOVA with Tukey’s post hoc test ( ## p < 0.01, ### p < 0.001 versus untreated control; ns, not significant; *p < 0.05, ***p < 0.01, ***p < 0.001 versus cells treated with IL-6 or IL-4). ESB, ethanolic extract of Scutellaria baicalensis root; IL, interleukin; STAT3, signal transducer and activator of transcription 3.
Phospho Stat6 (Y641) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc12177566-81-3-9?v=Cell+Signaling+Technology+Inc
Average 90 stars, based on 1 article reviews
phospho-stat6 (y641) antibody - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc phospho stat6 y641 rabbit mab
(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of <t>STAT6</t> mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.
Phospho Stat6 Y641 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/bio_rxiv__2025__03__18__643177-260-48-64?v=Cell+Signaling+Technology+Inc
Average 93 stars, based on 1 article reviews
phospho stat6 y641 rabbit mab - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc p stat6 y641
(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of <t>STAT6</t> mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.
P Stat6 Y641, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/y641/pmc11506136-242-18-23?v=Cell+Signaling+Technology+Inc
Average 95 stars, based on 1 article reviews
p stat6 y641 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

Image Search Results


Effects of ESB on STAT3 phosphorylation in RAW 264.7 cells. RAW 264.7 mouse macrophages were stimulated with IL-6 (100 ng/mL, A, B) or IL-4 (100 ng/mL, C, D) in the presence or absence of ESB (50 and 100 μg/mL). After 24 h, the levels of phosphorylated and total STAT3 and STAT6 were analyzed using Western blot analysis. Actin served as a loading control. Representative blot images from three independent experiments are shown (A, C). The ratio of phosphorylated to total protein was quantified by measuring band intensity (B, D). Data are presented as the mean ± SD of three independent experiments. Statistical significance was evaluated using one-way ANOVA with Tukey’s post hoc test ( ## p < 0.01, ### p < 0.001 versus untreated control; ns, not significant; *p < 0.05, ***p < 0.01, ***p < 0.001 versus cells treated with IL-6 or IL-4). ESB, ethanolic extract of Scutellaria baicalensis root; IL, interleukin; STAT3, signal transducer and activator of transcription 3.

Journal: Journal of Pharmacopuncture

Article Title: Suppression of Macrophage Migration and M2 Polarization by an Ethanolic Extract of Scutellaria baicalensis Root

doi: 10.3831/KPI.2025.28.2.144

Figure Lengend Snippet: Effects of ESB on STAT3 phosphorylation in RAW 264.7 cells. RAW 264.7 mouse macrophages were stimulated with IL-6 (100 ng/mL, A, B) or IL-4 (100 ng/mL, C, D) in the presence or absence of ESB (50 and 100 μg/mL). After 24 h, the levels of phosphorylated and total STAT3 and STAT6 were analyzed using Western blot analysis. Actin served as a loading control. Representative blot images from three independent experiments are shown (A, C). The ratio of phosphorylated to total protein was quantified by measuring band intensity (B, D). Data are presented as the mean ± SD of three independent experiments. Statistical significance was evaluated using one-way ANOVA with Tukey’s post hoc test ( ## p < 0.01, ### p < 0.001 versus untreated control; ns, not significant; *p < 0.05, ***p < 0.01, ***p < 0.001 versus cells treated with IL-6 or IL-4). ESB, ethanolic extract of Scutellaria baicalensis root; IL, interleukin; STAT3, signal transducer and activator of transcription 3.

Article Snippet: Phospho-STAT3 (Y705) and phospho-STAT6 (Y641) antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).

Techniques: Phospho-proteomics, Western Blot, Control

(A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of STAT6 mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.

Journal: bioRxiv

Article Title: Multidimensional characterization of cellular ecosystems in Hodgkin lymphoma

doi: 10.1101/2025.03.18.643177

Figure Lengend Snippet: (A) Cohort and study design overview. We analyzed whole exome and targeted sequencing data from 114 CHL fresh frozen samples, including 103 patients treated with ABVD-based regimens. Subsequently, we developed tissue microarrays of the cohort and applied whole transcriptome sequencing of CD30+ HRS cells using Nanostring GeoMx technology as well as multiplexed analysis using imaging mass cytometry. Key findings were validated using an independent validation cohort (n=293). (B) Oncoplot showing the most recurrently mutated genes within the CHL samples in the discovery cohort, with clinical annotations. (C) Significantly amplified (red) or deleted (blue) regions across our in-house CHL cohort. (D) Pairwise (Fisher’s exact test) comparison of the incidence of mutations within thymic vs non-thymic CHL cases. The size of the point indicating the strength of association. (E) Frequency of STAT6 mutations in CHL according to age group (YOUNG: < 45 years, OLD: 45 years or older) at diagnosis. YOUNG: < 45 years. Fisher’s exact test was used to determine the significance of differences in observed mutational frequencies. (F) Progression-free survival (PFS) according to mutation and copy number status of STAT6 in young CHL patients (age < 45). P -values were calculated using a log rank test.

Article Snippet: Immunoblotting was performed as previously described( Alig et al ., 2023 ) using the following primary antibodies: STAT1 Rabbit mAb (D1K9Y), STAT3 Mouse mAb (124H6), STAT6 Rabbit mAb (D3H4), AKT(pan) Rabbit mAb (C67E7), Phospho-STAT1 (Y701) Rabbit mAb (58D6), Phospho-STAT3 (Y705) Rabbit mAb (D3A7), Phospho-STAT5 (Y694) Rabbit mAb (C11C5), Phospho-STAT6 (Y641) Rabbit mAb (C11A12), Phospho-AKT (S473) Rabbit mAb (193H12), GAPDH Rabbit mAb (14C10) (all from Cell Signaling Technology, dilution 1:1000), STAT5 Rabbit polyclonalAb (C-17) (dilution 1:5000), CSF2RB (IL-3/IL-5/GM-CSFRβ Mouse mAb (A-3) (dilution 1:100) (Santa Cruz Biotechnology), followed by secondary staining using anti-Mouse (dilution 1:10000; Promega, catalog no. W4021) or Rabbit IgG (H+L) HRP conjugate (dilution 1:5000; Promega, catalog no. W4011), and detected using Amersham ECL Detection Reagents (Cytiva, catalog no. RPN3004).

Techniques: Sequencing, Imaging, Mass Cytometry, Amplification, Comparison, Mutagenesis